Trial: 202003148

A single arm, multicenter, phase 2 trial to evaluate the efficacy of lenvatinib (LEN) in combination with pembrolizumab (KEYtruda) in subjects with locally advanced or metastatic Non-clear cell renal cell carcinoma (The LENKYN Trial)

Phase

II

Principal Investigator

Picus, Joel

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov